This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Optimal care and survival for signet-ring cell and non-signet-ring cell gastric cancer are more achievable at academic cancer centers
Am J Surg. 2021 May 23
AbstractBACKGROUND: Western literature lacks large-scale population studies comparing the influence of academic and high-volume (HV) versus low-volume (LV) cancer centers on gastric cancer oncologic outcomes. METHODS: The National Cancer Database from 2004 to 2016 was used. RESULTS: 22871 patients were studied. Patients with stage III signet-ring cell gastric carcinoma (SRGC) received neoadjuvant treatment (NAT) more frequently at academic and HV comprehensive cancer centers (OR: 4.27 and 2.42; p < 0.0001 and 0.009) compared to community centers. Patients with stage III non-SRGC (NSRGC) had a 2.4 times higher odds of receiving NAT at academic centers. The R1 resection rate for NSRGC was lower at academic centers (OR: 0.67; p = 0.0018). Lymph node harvest ≥15 nodes was 1.6 and 1.9 times higher at academic centers for NSRGC and SRGC, respectively. Patients treated at academic centers had a significantly improved overall survival (OS). CONCLUSIONS: Treatment at academic centers is associated with significant improvements in oncologic metrics and OS.
Notes1879-1883 Moslim, Maitham A Deng, Mengying Handorf, Elizabeth Greco, Stephanie H Farma, Jeffrey M Journal Article United States Am J Surg. 2021 May 23:S0002-9610(21)00287-7. doi: 10.1016/j.amjsurg.2021.05.007.